SCHEMBL27218937

SCHEMBL27218937

Oc1cc(C(F)(F)F)nc(SCc2ncc(-c3cccc(C(F)(F)F)c3)o2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ USP2 O75604 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ GAA P10253 2/20 0.39
▸ ATM Q13315 1/20 0.39
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38
▸ HSD17B10 Q99714 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ SIGMAR1 Q99720 1/20 0.37
▸ RAB9A P51151 3/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ GRK6 P43250 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.35
▸ TSHR P16473 1/20 0.35
▸ NPC1 O15118 2/20 0.35
▸ CLK1 P49759 1/20 0.35
▸ GFER P55789 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27218724 0.90 ALDH1A1 (0.43) ALDH1A1L3MBTL1SMN1; SMN2USP2HPGD
SCHEMBL27218924 0.89 ALDH1A1 (0.47) ALDH1A1L3MBTL1SMN1; SMN2USP2HPGD
SCHEMBL27218940 0.89 FFAR1 (0.40) ALDH1A1L3MBTL1SMN1; SMN2USP2HPGD
SCHEMBL27218747 0.87 ALDH1A1 (0.39) ALDH1A1L3MBTL1SMN1; SMN2USP2HPGD
SCHEMBL27218819 0.86 VCP (0.42) ALDH1A1L3MBTL1SMN1; SMN2USP2HPGD
SCHEMBL27218657 0.85 ALDH1A1 (0.37) ALDH1A1L3MBTL1SMN1; SMN2USP2HPGD
SCHEMBL27218779 0.83 ALDH1A1 (0.42) ALDH1A1L3MBTL1SMN1; SMN2USP2HPGD
SCHEMBL27218749 0.82 POLB (0.39) ALDH1A1L3MBTL1SMN1; SMN2USP2HPGD
SCHEMBL27218723 0.81 MAPT (0.48) ALDH1A1L3MBTL1SMN1; SMN2HPGDHSD17B10
SCHEMBL27218692 0.79 NOTUM (0.43) ALDH1A1L3MBTL1SMN1; SMN2USP2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 — — EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 — — EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 ALDH1A1 1767/4885L3MBTL1 1935/4885SMN1; SMN2 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback